<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Biochemistry</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/53F60C78-5B20-4508-BEFE-30364228050F"><gtr:id>53F60C78-5B20-4508-BEFE-30364228050F</gtr:id><gtr:name>Cambridge Enterprise</gtr:name><gtr:address><gtr:line1>10 Trumpington Street</gtr:line1><gtr:postCode>CB2 1QA</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/583CDDE1-FE21-497C-BEC2-80C54F20AD61"><gtr:id>583CDDE1-FE21-497C-BEC2-80C54F20AD61</gtr:id><gtr:firstName>Peter Anthony</gtr:firstName><gtr:surname>McNaughton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/25BE204C-43DB-44C5-B3EA-2657E3F207C2"><gtr:id>25BE204C-43DB-44C5-B3EA-2657E3F207C2</gtr:id><gtr:firstName>Katherine</gtr:firstName><gtr:otherNames>Mary</gtr:otherNames><gtr:surname>Stott</gtr:surname><gtr:orcidId>0000-0002-4014-1188</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FN022181%2F1"><gtr:id>9B2A8DCF-D522-44ED-8DE7-CA12B320A015</gtr:id><gtr:title>Novel analgesics based on antagonism of TRPV1-AKAP79 binding</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/N022181/1</gtr:grantReference><gtr:abstractText>Pain is a significant clinical problem, because all existing analgesics have major side effects and are also poorly effective in many clinically important types of pain. A membrane ion channel, TRPV1, which is activated by heat, is critical for pain because when tissues are damaged, inflammatory mediators lower the temperature threshold of TRPV1 so that it can be activated even by normal body heat and thus cause ongoing pain. We have discovered how to prevent the effects of inflammatory mediators on TRPV1. A scaffolding protein, AKAP79, forms a &amp;quot;basket&amp;quot; structure which holds close to TRPV1the enzymes responsible for lowering its threshold. We have identified the binding site and can prevent binding using competitor peptides. These peptides give good analgesia in a mouse models of pain, including in a model of diabetic neuropathy, an intractable human pain condition. We will develop improved TRPV1-AKAP79 blocking peptides as better analgesics for intractable forms of pain.</gtr:abstractText><gtr:fund><gtr:end>2019-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2016-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>732820</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">BB/N022181/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>